ASLAN Refills Pipeline With Homegrown Immuno-Onc Asset

Singapore's ASLAN has signed its second deal in the past few weeks, acquiring global rights to an early stage immuno-oncology molecule that helps to fill a pipeline hole left by a recent out-licensing deal with Bristol-Myers Squibb.